Exp Clin Psychopharmacol
August 1, 2016
Albert Garcia‐romeu, Brennan Kersgaard, Peter H. Addy
198 citations
Hallucinogens fall into several different classes, as broadly defined by pharmacological mechanism of action, and chemical structure. These include psychedelics, entactogens, dissociatives, and other atypical hallucinogens. Although these classes do not share a common primary mechanism of action, they do exhibit important similarities in their ability to occasion temporary but profound...
Progress in neuro-psychopharmacology & biological psychiatry
January 4, 2016
Alicia Danforth, Christopher M Struble, Berra Yazar-Klosinski et al.
110 citations
The first study of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for the treatment of social anxiety in autistic adults commenced in the spring of 2014. The search for psychotherapeutic options for autistic individuals is imperative considering the lack of effective conventional treatments for mental health diagnoses that are common in this population. Serious Adverse Events (SAEs)...
Translational Psychiatry
September 15, 2015
Matthew B Young, Raül Andero, Kerry J. Ressler et al.
137 citations
Abstract Acutely administered 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’) has been proposed to have long-term positive effects on post-traumatic stress disorder (PTSD) symptoms when combined with psychotherapy. No preclinical data support a mechanistic basis for these claims. Given the persistent nature of psychotherapeutic gains facilitated by MDMA, we hypothesized that MDMA improves...
Human Psychopharmacology Clinical and Experimental
July 1, 2015
Giulia Francesconi, Laura Orsolini, Duccio Papanti et al.
22 citations
INTRODUCTION: Venlafaxine is one of the most frequently prescribed antidepressants worldwide, despite its toxicity risk in overdose. Furthermore, the molecule has been recently identified at the EU-wide level as one of the novel psychoactive substances. This paper aims at investigating the potential of misuse, taking into account both the existing literature and the analysis of the misusers'...
Behavioural Pharmacology
September 1, 2014
María Pilar García-pardo, Marta Rodrı́guez-arias, Concepción Maldonado et al.
29 citations
Exposure to social defeat stress increases the rewarding effects of psychostimulants in animal models, but its effect on 3,4-methylenedioxymethylamphetamine (MDMA) reward has received little attention. In the present study, we evaluated the influence of social defeat on the rewarding effects of MDMA in adolescent [postnatal day (PND) 29-40] and adult (PND 50-61) male mice using the conditioned...
Brazilian Journal of Medical and Biological Research
September 4, 2013
V. Ferraz-De-Paula, D. Stankevicius, A. Ribeiro et al.
10 citations
Anxiolytic and anxiogenic-like behavioral outcomes have been reported for methylenedioxymethamphetamine (MDMA or ecstasy) in rodents. In the present experiment, we attempted to identify behavioral, hormonal and neurochemical outcomes of MDMA treatment to clarify its effects on anxiety-related responses in 2-month-old Balb/c male mice (25-35 g; N = 7-10 mice/group). The behavioral tests used...
Clínica y Salud
2010
Lisa Wood, Barkus Emma
1 citation
Aims: The relationship between ecstasy and affective psychological symptoms are still subject to debate. We aimed to examine the relationship between Ecstasy use and self-report depression, anxiety and schizotypy. Design: Data were collected via structured remote self-report questionnaires. Participants: Participants were split into three groups: a control group with no ecstasy use, a light...
Journal of Psychopharmacology
March 9, 2009
P.-ø. Johansen, Ts Krebs
98 citations
Abstract Exposure therapy is known to be an effective treatment for anxiety disorders. Nevertheless, exposure is not used as much as it should be, and instead patients are often given supportive medications such as serotonin reuptake inhibitors (SSRIs) and benzodiazepines, which may even interfere with the extinction learning that is the aim of treatment. Given that randomized controlled trials...
Journal of Psychopharmacology
August 22, 2007
Rüssel S. Falck, Jichuan Wang, Robert G. Carlson
45 citations
Research suggests that methylenedioxymethamphetamine (MDMA)/`ecstasy' can cause serotonin depletion as well as serotonergic neurodegradation that may result in depression. This longitudinal study used the Beck Depression Inventory (BDI-II) to assess depressive symptomatology every six months over a two-year period among a community sample of young adult MDMA/`ecstasy' users ( n = 402)....
Annals of the New York Academy of Sciences
August 1, 2006
Raquel Faria, Ana Magalhães, Pedro Monteiro et al.
29 citations
Abstract: Long‐term behavioral consequences of the neurotoxicity produced by 3,4‐methylenedioxymethamphetamine (MDMA) in the adolescent rat are still mostly unknown. Here, adolescent male rats (postnatal day 45 PND [45]) were exposed to 10 mg/kg of MDMA, intraperitoneally, every 2 h for 6 h. Controls were given 0.9% saline in the same protocol. Ten days after exposure, the behavioral effects of...